Nitinotes is focused on revolutionizing obesity treatment through its non-invasive Endozip product. The company frames its mission as transcending traditional healthcare paradigms and setting new standards in the field. It closed a $10.1M Series B to advance its clinical and commercial objectives. The capital will be used to complete EU clinical studies and secure the CE mark. Proceeds will also support preparations for entering the EU market. Nitinotes is in advanced stages of developing the next iteration of the Endozip product, and describes the funding as a strong endorsement of its vision and team. Nitinotes is developing the Endozip automated endoscopic suturing system. The company announced closing an internal $7.1M Series A1 funding round on May 10, 2020. The raise brought Nitinotes' total funding to $13.5M. Proceeds will be used to finalize Endozip development and to execute a multi-center pilot study in the EU. The announcement framed the round as internal and did not disclose external investor names.

Total raised

$17M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2023